SeaSpine Holdings Corporation Stock News

SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CARLSBAD, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disor

CARLSBAD, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorde

CARLSBAD, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disor

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disor

SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine press release (SPNE): Q4 GAAP EPS of -$0.52 misses by $0.20.Revenue of $55.6M (+19.8% Y/Y) beats by $0.24M.Shares +1.34%.

Provides 2022 Revenue Guidance Provides 2022 Revenue Guidance

CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal diso

Alphatec (ATEC) delivered earnings and revenue surprises of -29.03% and 0.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Announces Date of Fourth Quarter and Full Year 2021 Financial Results Conference Call Announces Date of Fourth Quarter and Full Year 2021 Financial Results Conference Call

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.